August 2012
-
Particle engineering specialist Hovione, which recently announced plans to increase its global capacity by 25%, has announced that a portion of its $170 million expansion project will go toward a 31,000 sq ft building to… Read more . . .
-
Kindeva Drug Delivery announced that it will install a new MDI manufacturing line capable of filling either HFA-152a or HFO-1234ze, both of which have a lower global warming potential (GWP) than HFA 134a. The new… Read more . . .
-
According to Tonix Pharmaceuticals, the FDA has cleared the company’s IND for a Phase 2 study of TNX-1900 potentiated oxytocin nasal spray for the prevention of migraine headache. Tonix acquired the rights to the intranasal… Read more . . .
-
Strados Labs announced that its RESP Smart Sensor Platform, which remotely measures and records lung sounds for use in respiratory disease treatment and clinical trials, has been granted a CE mark. According to Strados, a… Read more . . .
-
According to DPI developer Iconovo, TOA Pharmaceutical has signed a new agreement for the use of an Iconovo dry powder inhaler for a feasibility study. TOA will pay €202,000 over the next year for use… Read more . . .
-
Brigham and Women’s Hospital (BWH) has announced an upcoming clinical trial of an intranasal vaccine for the prevention and treatment of Alzheimer’s disease (AD). The SAD trial is expected to enroll 16 early-staged Alzheimer’s patients aged… Read more . . .
-
According to Inhalation Sciences (ISAB), Akari Therapeutics has chosen ISAB’s CRO, Inhalation Research Services, to conduct a pharmacokinetic study of Akari’s Nomacopan, a C5 and LTB4 inhibitor that the company is evaluating as an inhaled… Read more . . .
-
Padagis (formerly Perrigo’s generic prescription pharmaceutical business) has announced the launch of its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. Altaris acquired Padagis… Read more . . .
-
CDMO Hovione said that it is investing $170 million to increase overall capacity at its manufacturing facilities in Portugal, Ireland, and the US by about 25% to meet strong demand. According to the company, its… Read more . . .
-
For the second year, the Drug Delivery to the Lungs conference will take place virtually as a result of the COVID-19 pandemic. The conference will include both live and recorded scientific presentations, live discussion sessions,… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.